Fund moves
1.79MShares reported
3 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ANL · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
Adlai Nortye Group (ANL) · oqro.io/stocks/ANL · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$8.55−0.51 (−5.63%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Adlai Nortye Group is on record in SEC filings since 2006.
No open-market sale by an insider of Adlai Nortye Group (ANL) was filed with the SEC in the last 90 days.
No trade in Adlai Nortye Group (ANL) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+497.9% (+$7.12) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $1.43 on Nov 20, 2025 to $8.55 on Nov 20, 2026 (+497.9%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Singapore. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
+497.9%
Market value
–
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 5.8M shares sold short, +13.8% vs the previous count, 27.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Fund moves
3 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest annual report filed Apr 10, 2026, compared with the one filed Apr 30, 2025. Read the filing
Source: SEC EDGAR, Form 20-F filed Apr 10, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 6,000 words.
We are a global clinical-stage company at the forefront of discovering and developing innovative cancer therapies. Leveraging our dual R&D presence in the U.S. and China, we are building a robust pipeline of drug candidates focused on two key areas where we believe we can make a significant difference. (1) RAS-targeting therapies: we are tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 20-F filed Apr 10, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
0 certified in FY2026 Q3, vs 0 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
No Schedule 13D or 13G filing on ANL over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Off-exchange trading: 55.1% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (34.8% on ATS, 20.3% with other brokers), above its 26-week average of 47.0%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INSTINCT X (14.9%), UBS ATS (13.1%), LIQUIDNET NEGOTIATION ATS (11.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.